Sandoz Group AG (SDZ.SW)
Sandoz Group AG (SDZ.SW) Stock Price, Analysis & Data
No hay datos disponibles
| Precio de compra | 73.76 |
| Capitalización de mercado | 31.92B |
| Ingresos (TTM) | 11.68B |
| Beneficio neto (TTM) | 646M |
| Beta | 0.49 |
| EPS (TTM) | 1.2 |
| Ratio PER (TTM) | 62.51 |
| Adelante PE | 19.96 |
| P/B (TTM) | 4.20 |
| P/S (TTM) | 2.73 |
| Earnings Date | Feb 17, 2027 |
| Precio de venta | 73.8 |
| Volumen | 194,412 |
| Volumen medio (20D) | 746,109 |
| Abierto | 73.12 |
| Anterior Cerrar | 73.40 |
| Rango del día | 73.12 - 74.26 |
| Rango de 52 semanas | 43.86 - 75.90 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | $0.8 (1.09%) |
| Fecha ex dividendo | 13 abr 2026 |
Acerca de SDZ.SW
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage...
Desempeño financiero
En 2025, los ingresos de Sandoz fueron 11.16B, un aumento de 7.44% en comparación con 10.38B del año anterior. Las ganancias fueron 914M, un aumento de undefined%.
Cifras financieras en CHF Estados financierosLos analistas proyectan ingresos de ... Actualizar
2 semanas hace · The Wall Street Journal
Sandoz in Talks With U.S. Government About Potential Investment, CEO SaysSandoz Group is in talks with the U.S. government about manufacturing investments in the country and doesn’t see President Trump’s planned tariffs on generic medicines as a major threat, the drugmaker...